Drugs / V512
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00851266 | Oct 2006 → Aug 2007 | influenza | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | V512 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00851266 ↗ |
| Known as | BIPCV/IMX | “This is a first in man study evaluating the tolerability and immunogenicity of BIPCV/IMX (V512) at increasing concentrations of influenza viral peptides A/M2+B/HA0 peptides and...” NCT00851266 ↗ |